Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by, and welcome to Kentra Bio's fourth quarter and full year 2025 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. To remove yourself from the queue, you may press star 1-1 again. I would now like to hand the call over to Gaia Shamus, with LifeSci Advisors. Please go ahead. Thank you, operator. Good afternoon, everyone. Thank you for joining today to discuss KintraBio's fourth quarter and full year 2025 financial and business results. I'm Gaia Chamis from LifeSci Advisors. Joining me on today's call are Zane Wettig, Chief Executive Officer, David Ilchia, Chief Financial Officer, and Carol Gedum, Vice President of Product Development. Following the prepared remarks, we will open the call to your questions. I would like to remind you that remarks made on today's call include forward-looking statements about Kintra Bio. Such statements may include, but are not limited to, collaborations with AstraZeneca and Astellas, financial guidance, the initiation, enrollment, design, conduct, and results of clinical trials, regulatory strategies and potential regulatory results, research and development activities, commercial results and results of operations, risks related to our business, and certain other business matters. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Kintra BIOS filing with the SEC, including our most recent Form 10-K and Form 10-Q. Kintra ...